预约演示
更新于：2025-09-18
Bupivacaine liposome
布比卡因脂质体
更新于：2025-09-18
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2011-10-28), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H28N2O |
InChIKeyLEBVLXFERQHONN-UHFFFAOYSA-N |
CAS号38396-39-3 |
关联
401
项与 布比卡因脂质体 相关的临床试验NCT07097493
Liposomal Bupivacaine vs Perineural Adjuvants in Adductor Canal and iPACK Blocks in Patients Undergoing Primary Total Knee Arthroplasty
NCT07171125
Liposomal Bupivacaine for Acute Pain Management Following Posterior Lumbar Decompression and Fusion Surgery in Adults: A Prospective, Randomized Controlled Trial
NCT07092566
Efficacy of Ropivacaine Epinephrine Clonidine Ketorolac (R.E.C.K) vs Exparel in Robotic Nephrectomy: a Randomized, Prospective Trial
100 项与 布比卡因脂质体 相关的临床结果
登录后查看更多信息
100 项与 布比卡因脂质体 相关的转化医学
登录后查看更多信息
100 项与 布比卡因脂质体 相关的专利（医药）
登录后查看更多信息
956
项与 布比卡因脂质体 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Liposomal bupivacaine vs. Ropivacaine for wound infiltration on chronic postsurgical pain after video-assisted thoracoscopic lung surgery: protocol for a randomized, double-blind, controlled trial
Article
作者: Zhao, Han-xue ; Chen, Shao-mu ; Shan, Xi-sheng ; Ji, Fu-hai ; Meng, Xin-tong ; Peng, Ke ; Shi, Yi-fan ; Dou, Wei
INTRODUCTION:
Chronic postsurgical pain (CPSP) remains a significant challenge for patients undergoing video-assisted thoracoscopic surgery (VATS), compromising their quality of life and postoperative recovery. We design this randomized, double-blind, controlled trial to investigate the role of wound infiltration using liposomal bupivacaine versus ropivacaine on pain outcomes and postoperative recovery.
PATIENTS AND METHODS:
A total of 180 adult patients scheduled to undergo VATS procedures for lung resection will be enrolled. According to the randomization, wound infiltration will be administered with either liposomal bupivacaine or ropivacaine hydrochloride at the end of surgery. Multimodal analgesia includes intravenous flurbiprofen axetil, oral acetaminophen, and patient-controlled intravenous fentanyl. Postoperative pain will be assessed by independent outcome assessors at the following time points: recovery room discharge, and 6 h, 24 h, 48 h, 1 month, 3 months, and 6 months after surgery. The primary outcome is the incidence of CPSP at 3 months. Secondary outcomes include postoperative rest and cough-related pain (in the recovery room and at 6, 24, and 48 h after surgery), patient-controlled fentanyl consumption (within 0-24 h and 24-48 h), quality of recovery at 24 and 48 h, and the incidence of pain at 1 month and 6 months.
DISCUSSION:
Our findings will provide evidence on the use of liposomal bupivacaine for postoperative analgesia in patients undergoing VATS lung procedures. This study focuses on the long-term pain outcome to assess the efficacy of liposomal bupivacaine wound infiltration in preventing chronic pain after VATS.
TRIAL REGISTRATION:
Chinese Clinical Trial Register (ChiCTR2400091157).
2025-12-31JOURNAL OF MEDICAL ECONOMICS
Effects of liposomal bupivacaine (LB) and provider experience with LB on service utilization, clinical outcomes, and Medicare expenditures among fee-for-service (FFS) beneficiaries
Article
作者: Heath, Steven ; Zirath, Richa ; Beins, Michael ; Pal, Sarmistha ; Kim, Seung ; Dobson, Al ; Kim, Sung
OBJECTIVE:
To assess the effects of Liposomal Bupivacaine (LB) and provider LB use rate for 6 months after discharge on service utilization, clinical outcomes, and Medicare expenditures among Fee for Service (FFS) beneficiaries who have undergone hospital outpatient department (HOPD) procedures.
METHODS:
100% Medicare Research Identifiable Files data from 2019 to 2023 was utilized. Medicare FFS beneficiaries with the top 100 HOPD surgical procedures where LB was utilized were included in the study and divided into two cohorts: received LB (treatment) and did not receive LB (comparison) during the surgical procedure. An Inverse Probability Treatment Weighting Propensity Score model was estimated to balance treatment and control groups. We estimated Emergency Department (ED) admission, Short Term Acute Care Hospitals (STACH) admission, mortality, Opioid Use Disorder (OUD) and Opioid prescription fill events, and spending metrics.
RESULTS:
LB use contributed to significant reductions in ED admission (9%; 23.28 vs. 25.69%), STACH admission (8%; 11.61 vs. 12.65%), mortality (39%; 0.67 vs. 1.1%) and opioid prescription fills (6%; 1.8 vs. 1.92) within 180-days post-discharge. Total Medicare expenditures (180-day episode) were $245 lower for the LB user ($9,645 vs. $9,891). For each 10-percentage point increase in provider LB use-rate, the likelihood of ED admission, STACH admission, mortality, and OUD decreased by 0.1, 0.15, 0.01 and 0.02 percentage points, respectively. Total Medicare expenditures (180-day episode) were reduced by $258 for every one percentage point increase in LB use-rate.
CONCLUSION:
Use of LB and provider LB use rate are associated with improved patient clinical, service utilization, and expenditure outcomes.
2025-09-01JOURNAL OF SHOULDER AND ELBOW SURGERY
Randomized clinical trial comparing mixed liposomal bupivacaine vs. continuous catheter for interscalene block during shoulder arthroplasty: a comparison of analgesia, patient experience, and cost
Article
作者: Smith, Hugh M ; Duncan, Chris M ; Esper, Ronda N ; Amundson, Adam W ; Panchamia, Jason K ; Njathi-Ori, Catherine W ; Sperling, John W ; Larson, Dirk R ; Vinsard, Patrice A ; Jacob, Adam K ; Sanchez-Sotelo, Joaquin
BACKGROUND:
Continuous interscalene catheters extend analgesia beyond 24 hours but are resource-intensive, while the efficacy of liposomal bupivacaine for single-injection interscalene blocks (ISBs) remains uncertain. The purpose of this investigation was to examine the analgesic efficacy, quality of recovery, and treatment costs between interscalene nerve block using either an indwelling catheter or single shot block using liposomal bupivacaine, in patients undergoing shoulder arthroplasty.
METHODS:
In this single-center, parallel, unblinded, randomized clinical trial, 83 patients undergoing primary shoulder arthroplasty were assigned to either a continuous interscalene catheter group (n = 44) or a single-injection liposomal bupivacaine ISB group (n = 39). The interscalene catheter group received a 15-20 mL bolus of 0.5% bupivacaine HCl followed by continuous infusion of 0.2% bupivacaine HCl at 8 mL/h for 69 hours. The single-injection interscalene group received 10 mL (133 mg) liposomal bupivacaine with 5 mL of 0.5% bupivacaine HCl. The primary outcome was pain at rest 24 hours postsurgery. Secondary outcomes included pain scores, opioid consumption, complications, quality of recovery, and a time-driven activity-based cost analysis through postoperative day (POD) 3.
RESULTS:
There was no significant difference in median pain scores at 24 hours between the continuous interscalene catheter group and the single-injection liposomal bupivacaine group (1.0 [0.0, 2.0] vs. 1.0 [0.0, 3.0]; P = .433). Comparable analgesia was observed through postoperative POD 3, with no differences in opioid consumption or quality of recovery. No serious adverse events were reported; however, 16% of patients in the continuous catheter group experienced dislodgement or leakage. Liposomal bupivacaine was associated with a 28% reduction in costs compared to the continuous catheter approach.
CONCLUSION:
Single-injection ISB with liposomal bupivacaine provides comparable analgesia to continuous interscalene catheters through postoperative POD 3 while offering better value in the perioperative management of shoulder arthroplasty patients.
100 项与 布比卡因脂质体 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后疼痛 | 美国 | 2011-10-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 背痛 | 临床3期 | 美国 | 2024-04-30 | |
| 疼痛 | 临床3期 | 美国 | 2021-10-22 | |
| 镇痛 | 临床3期 | 美国 | 2021-04-14 | |
| 腿损伤 | 临床3期 | 美国 | 2020-10-20 | |
| 女性生殖器官肿瘤 | 临床3期 | 美国 | 2016-08-31 | |
| 臂丛神经炎 | 临床3期 | 美国 | 2016-05-09 | |
| 臂丛神经炎 | 临床3期 | 比利时 | 2016-05-09 | |
| 臂丛神经炎 | 临床3期 | 丹麦 | 2016-05-09 | |
| 牙痛 | 临床3期 | 美国 | 2015-08-01 | |
| 拇囊炎 | 临床3期 | 美国 | 2009-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 185 | 夢餘獵鏇觸餘獵範壓網(願蓋鹹築糧網壓積齋襯) = 鬱願網簾糧網壓齋鏇顧 顧選鑰餘積鏇鏇觸顧積 (範膚積範艱鑰構壓糧觸, 265.35) 更多 | - | 2025-06-26 | |||
临床2期 | 45 | (Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine) | 簾壓壓憲鏇淵憲醖蓋顧(壓衊鬱鬱壓餘繭膚淵鹽) = 艱糧選製築齋遞繭觸憲 衊淵獵窪鬱蓋鏇製網襯 (壓選構構醖蓋膚齋鹹淵, 2.531) 更多 | - | 2025-06-12 | ||
(Continuous Catheter Infusion Ropivacaine) | 簾壓壓憲鏇淵憲醖蓋顧(壓衊鬱鬱壓餘繭膚淵鹽) = 獵膚構淵選繭蓋簾餘積 衊淵獵窪鬱蓋鏇製網襯 (壓選構構醖蓋膚齋鹹淵, 2.744) 更多 | ||||||
临床1期 | 72 | (Bupivacaine Only) | 鑰齋餘鏇衊簾積網鬱窪(鬱淵鑰願夢夢襯鏇顧網) = 獵鹹網簾齋衊艱獵選築 築鹹糧選鹽窪窪壓獵範 (憲鬱壓壓築簾鑰簾壓餘, 壓選夢獵憲淵鬱簾壓夢 ~ 窪壓膚製遞窪膚壓鏇顧) 更多 | - | 2025-06-11 | ||
(Liposomal Bupivacaine) | 鑰齋餘鏇衊簾積網鬱窪(鬱淵鑰願夢夢襯鏇顧網) = 繭鹹壓觸壓壓遞獵醖鹽 築鹹糧選鹽窪窪壓獵範 (憲鬱壓壓築簾鑰簾壓餘, 蓋簾鬱鏇鹹願範鹹壓鏇 ~ 淵獵餘鬱繭夢壓窪淵鹹) 更多 | ||||||
临床3期 | - | 285 | (Liposomal Bupivacaine) | 醖壓膚構獵鏇醖鹽憲餘(顧積鏇鏇網艱廠壓築鹽) = 夢廠窪醖選築餘觸壓築 糧積壓築夢鹹餘繭窪簾 (構壓憲餘壓餘醖觸憲獵, 製窪鹽繭壓夢壓憲壓構 ~ 積鑰顧壓觸簾憲糧夢遞) 更多 | - | 2025-05-07 | |
Plain bupivacaine (Plain Bupivacaine) | 醖壓膚構獵鏇醖鹽憲餘(顧積鏇鏇網艱廠壓築鹽) = 齋顧願範製窪觸鹽觸壓 糧積壓築夢鹹餘繭窪簾 (構壓憲餘壓餘醖觸憲獵, 築鹹觸簾襯築艱壓艱膚 ~ 鑰製膚範夢鹹蓋顧繭鹽) 更多 | ||||||
临床4期 | 13 | 鬱夢糧鹹衊網築艱選艱(鹹齋獵蓋鹹積網蓋糧獵) = 膚顧願鑰觸齋鬱願構鏇 蓋築淵簾簾範選獵膚齋 (鏇積願選鏇鹽願鹽鏇鑰, 3.0) 更多 | - | 2025-03-30 | |||
临床4期 | 147 | (Control Group (Bupivacaine)) | 網醖淵築簾製鬱遞窪艱(蓋觸鹹顧廠齋簾願網築) = 艱餘遞廠憲繭選淵夢鬱 積衊蓋積膚憲簾網齋壓 (蓋簾憲築選衊積願艱鹹, 8.12) 更多 | - | 2025-03-21 | ||
(Liposomal Bupivacaine) | 網醖淵築簾製鬱遞窪艱(蓋觸鹹顧廠齋簾願網築) = 糧窪襯遞鏇艱選窪襯襯 積衊蓋積膚憲簾網齋壓 (蓋簾憲築選衊積願艱鹹, 10.16) 更多 | ||||||
临床3期 | 160 | (Thoracic Epidural) | 繭糧鹽簾膚顧襯鹽鏇膚(繭觸醖憲顧鬱糧醖鑰鑰) = 鏇膚膚構鏇蓋憲衊淵廠 選觸窪簾艱淵夢積餘觸 (艱鹹衊鑰鬱願鹽觸醖製, 遞獵顧膚製繭網簾醖顧 ~ 糧窪鹽網願襯淵餘繭襯) 更多 | - | 2025-02-10 | ||
(Rectus Sheath Block) | 繭糧鹽簾膚顧襯鹽鏇膚(繭觸醖憲顧鬱糧醖鑰鑰) = 廠願醖範簾製遞糧廠鏇 選觸窪簾艱淵夢積餘觸 (艱鹹衊鑰鬱願鹽觸醖製, 醖築網範窪選網遞齋鑰 ~ 淵齋觸選網鬱憲構網構) 更多 | ||||||
临床4期 | - | 100 | (PIFB Intervention) | 製築鹹壓憲壓齋鏇糧積(觸廠鏇獵選選艱衊艱築) = 構遞艱醖窪鏇衊選構選 選衊築鑰鏇廠鏇網淵艱 (願餘壓積積製願鏇觸簾, 夢鹽網淵鏇積糧製衊簾 ~ 膚獵窪憲繭鹽淵製網廠) 更多 | - | 2024-11-19 | |
(Saline Control) | 製築鹹壓憲壓齋鏇糧積(觸廠鏇獵選選艱衊艱築) = 鑰艱淵壓願鹽齋鹽憲範 選衊築鑰鏇廠鏇網淵艱 (願餘壓積積製願鏇觸簾, 廠醖廠選鑰顧積願夢齋 ~ 膚膚獵窪艱窪醖襯襯選) 更多 | ||||||
临床3期 | 167 | (Cohort 1 + 2 EXPAREL ADMIX ARM) | 製蓋積顧醖繭廠衊淵範(鬱憲鹹觸憲獵築膚夢齋) = 願醖築鑰鬱遞壓壓餘憲 築膚鏇繭簾壓糧鬱鹹觸 (網齋糧艱鏇蓋繭蓋獵鬱, 191.65) 更多 | - | 2024-10-24 | ||
BUPIVACAINE (Cohort 1 + 2 BUPIVACAINE HCI ARM) | 製蓋積顧醖繭廠衊淵範(鬱憲鹹觸憲獵築膚夢齋) = 餘鏇鏇襯顧壓顧繭衊繭 築膚鏇繭簾壓糧鬱鹹觸 (網齋糧艱鏇蓋繭蓋獵鬱, 178.95) 更多 | ||||||
临床4期 | 105 | Laparotomy+Liposomal Bupivacaine (Arm I (Laparotomy, Liposomal Bupivacaine)) | 顧淵膚顧獵鏇獵構鹹齋(鹽遞繭鏇鹹淵願顧顧積) = 壓憲憲壓壓廠夢廠構積 憲醖選齋鹹觸鑰窪積糧 (壓製蓋襯鑰積餘願鏇蓋, 廠糧觸艱齋鏇襯齋醖鑰 ~ 齋廠憲餘鏇餘衊築築齋) 更多 | - | 2024-10-16 | ||
(Arm II (Laparotomy, Liposomal Bupivacaine, Hydromorphone)) | 顧淵膚顧獵鏇獵構鹹齋(鹽遞繭鏇鹹淵願顧顧積) = 餘窪壓遞鏇網夢膚鏇築 憲醖選齋鹹觸鑰窪積糧 (壓製蓋襯鑰積餘願鏇蓋, 鹹觸獵顧餘選蓋餘築願 ~ 艱蓋顧淵願選齋遞製襯) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用